Regenacy Pharmaceuticals is developing a novel, disease-modifying approach to treating peripheral neuropathies that goes beyond pain and symptom management to restore peripheral nerve function.
Our lead compound ricolinostat (ACY-1215) is an oral, selective inhibitor of the microtubule modifying enzyme HDAC6 with first-in-class potential, currently positioned to enter Phase 2 clinical trials. Our investigation of ricolinostat for diabetic, chemotherapy-induced and inherited peripheral neuropathies is based on compelling proof-of-concept preclinical studies demonstrating restoration of normal nerve function.
We were founded in December 2016 following the acquisition of Acetylon Pharmaceuticals by Celgene. Regenacy received exclusive rights to ricolinostat, a clinical stage, orally bioavailable, HDAC6 selective inhibitor, for a range of non-cancer disease indications. We also have a unique and proprietary portfolio of selective HDAC1,2 inhibitors with potential for treating cancer, hemoglobinopathies, and cognitive dysfunction.
Our lead compound ricolinostat (ACY-1215) is an oral, selective inhibitor of the microtubule modifying enzyme HDAC6 with first-in-class potential, currently positioned to enter Phase 2 clinical trials. Our investigation of ricolinostat for diabetic, chemotherapy-induced and inherited peripheral neuropathies is based on compelling proof-of-concept preclinical studies demonstrating restoration of normal nerve function.
We were founded in December 2016 following the acquisition of Acetylon Pharmaceuticals by Celgene. Regenacy received exclusive rights to ricolinostat, a clinical stage, orally bioavailable, HDAC6 selective inhibitor, for a range of non-cancer disease indications. We also have a unique and proprietary portfolio of selective HDAC1,2 inhibitors with potential for treating cancer, hemoglobinopathies, and cognitive dysfunction.
Location: United States, Massachusetts, Waltham
Employees: 1-10
Total raised: $39.3M
Founded date: 2016
Investors 2
| Date | Name | Website |
| - | 3E Biovent... | 3ebiovc.co... |
| - | Cobro Vent... | cobroventu... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 25.08.2022 | Series B | $9.3M | - |
| 26.03.2020 | Series A | $30M | - |
Mentions in press and media 12
| Date | Title | Description |
| 28.09.2022 | Portfolio Highlights: Clinical and Financial Updates of ABM, F5, AceLink, HAYA, Regenacy, and Arthrosi | SHANGHAI, Sept. 28, 2022 /PRNewswire/ -- As the investment division of Viva Biotech, Viva BioInnovator is committed to being a collaborative platform for Innovative Biotech companies from around the world. Over the past 2 months, our portfo... |
| 25.08.2022 | Regenacy Pharmaceuticals Inks $9.3M Series B | WALTHAM, MA, Regenacy Pharmaceuticals, a clinical-stage biopharmaceutical company, announced the closing of a $9.3 million Series B financing led by Cobro Ventures. >> Click here for more funding data on Regenacy Pharmaceuticals &... |
| 27.03.2020 | These health startups raised $124M in venture capital funding this week | Headquarters: Neuchatel, Switzerland Amount raised: 6 million Swiss francs ($6.3 million) A Swiss-U.S. startup, Aktiia has developed an optical blood pressure for the wrist and said Tuesday that it plans to use the money it has raised to ob... |
| 26.03.2020 | Regenacy Pharmaceuticals Raises $30 Million in Series A Financing | - |
| 25.03.2020 | Regenacy Pharmaceuticals Inks $30M in Series A | WALTHAM, MA, Regenacy Pharmaceuticals announced the closing of a $30 million Series A financing co-led by Cobro Ventures and Taiwania Capital Management. >> Click here for more funding data on Regenacy Pharmaceuticals >> To ... |
| 25.03.2020 | Regenacy Pharmaceuticals Secures $30M in Series A Financing | Regenacy Pharmaceuticals, a Waltham, Mass.-based clinical-stage biopharmaceutical company developing breakthrough treatments for diabetic and other peripheral neuropathies, closed a $30m Series A financing. The round was co-led by Cobro Ven... |
| 25.03.2020 | Regenacy Pharma snags $30M for diabetic neuropathy treatment | Treatments for diabetic peripheral neuropathy—nerve damage stemming from diabetes—tend to focus on managing pain. But Regenacy Pharmaceuticals’ approach aims to reverse the nerve damage that causes that pain, and the company has scored $30 ... |
| 25.03.2020 | Regenacy Pharma snags $30M for diabetic neuropathy treatment W h i t e p a p e r Weighing the Costs: | Treatments for diabetic peripheral neuropathy—nerve damage stemming from diabetes—tend to focus on managing pain. But Regenacy Pharmaceuticals’ approach aims to reverse the nerve damage that causes that pain, and the company has scored $30 ... |
| 25.03.2020 | Cobro Ventures Leads $30M Series A for Regenacy Pharmaceuticals | WALTHAM, Mass.--(BUSINESS WIRE)--Regenacy Pharmaceuticals, a clinical-stage biopharmaceutical company developing breakthrough treatments for diabetic and other peripheral neuropathies, today announced the closing of a $30 million Series A f... |
| 25.03.2020 | Regenacy Pharmaceuticals Raises $30M Series A | WALTHAM, Mass.--(BUSINESS WIRE)--Regenacy Pharmaceuticals, a clinical-stage biopharmaceutical company developing breakthrough treatments for diabetic and other peripheral neuropathies, today announced the closing of a $30 million Series A f... |
Show more